Eating Disorders News and Research

Latest Eating Disorders News and Research

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Timberline Knolls psychiatrist recommends patients to receive specialized care for co-occurring disorder

According to the American Psychiatric Association, at least three percent of the United States population has a co-occurring disorder, yet only eight percent of those suffering receive specialized treatment for both their mental illness and substance abuse disorders.

2 Dec 2010

Eating Disorder Hope partners with MyPyramid to help eating disorder sufferers

Eating Disorder Hope, a respected independent resource for sufferers of anorexia, bulimia and overeating disorders, has partnered with MyPyramid to help eating disorder sufferers find nutritional and healthy lifestyle support.

24 Nov 2010

Scientists identify gene variants associated with eating disorder

Scientists at The Children's Hospital of Philadelphia have identified both common and rare gene variants associated with the eating disorder anorexia nervosa.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

WaterBrook Press releases third edition of Hope, Help and Healing for Eating Disorders

WaterBrook Press recently released the third edition of Hope, Help and Healing for Eating Disorders, A Whole-Person Approach to Treatment of Anorexia, Bulimia and Disorder Eating. The newest edition of this 1995 bestseller on overcoming anorexia, bulimia and other eating disorders from Dr. Gregory L. Jantz, PhD, with Ann McMurray, features the most up-to-date information on body image, food addiction, nutrition and more.

15 Nov 2010

New Specialist Library offers treatment for eating disorders

Eating Disorder Hope, a respected independent resource for individuals suffering from anorexia, bulimia, binge eating and other body image and eating disorders, has expanded its Eating Disorder Specialist Library to further help sufferers of anorexia, bulimia and binge eating disorder find treatment options.

30 Oct 2010

Women with anorexia nervosa at risk of unplanned pregnancies and induced abortions

A new study by University of North Carolina at Chapel Hill and Norwegian researchers has found that women with anorexia nervosa are much more likely to have both unplanned pregnancies and induced abortions than women who don't have the serious eating disorder.

30 Oct 2010

Eating disorders negatively affect oral health

While the connection between oral health and systemic health has been well-established, what most people don't know is that dentists often are in a position to detect systemic conditions. According to an article published in the October 2010 issue of AGD Impact, the monthly newsmagazine of the Academy of General Dentistry (AGD), dentists may be the first health care providers to notice evidence of an eating disorder, such as anorexia nervosa, bulimia nervosa, binge eating disorder, and pica.

29 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

A study presented at the American Society of Anesthesiologists 2010 Annual Meeting in San Diego seems to confirm that a single, small dose of the steroid dexamethasone improves the post-surgical quality of life of patients receiving laparoscopic gallbladder surgery.

20 Oct 2010

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification.

13 Oct 2010

Eating Disorders News and Research

Latest Eating Disorders News and Research

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Timberline Knolls psychiatrist recommends patients to receive specialized care for co-occurring disorder

Eating Disorder Hope partners with MyPyramid to help eating disorder sufferers

Scientists identify gene variants associated with eating disorder

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

WaterBrook Press releases third edition of Hope, Help and Healing for Eating Disorders

New Specialist Library offers treatment for eating disorders

Women with anorexia nervosa at risk of unplanned pregnancies and induced abortions

Eating disorders negatively affect oral health

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Dexamethasone improves quality of life after laparoscopic gallbladder surgery

Alkermes' VIVITROL medication for treatment of opioid dependence

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eating Disorders News and Research

Latest Eating Disorders News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in